| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/PHAR.1220 |
| P698 | PubMed publication ID | 23307539 |
| P50 | author | Keith Kaye | Q67189864 |
| Michael J Rybak | Q106082725 | ||
| Ravina Kullar | Q117264083 | ||
| P2093 | author name string | Donald P Levine | |
| Susan L Davis | |||
| Jason M Pogue | |||
| P2860 | cites work | Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia | Q28145964 |
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. | Q30977541 | ||
| Novel multiplex PCR assay for characterization and concomitant subtyping of staphylococcal cassette chromosome mec types I to V in methicillin-resistant Staphylococcus aureus | Q34073407 | ||
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary | Q34158152 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship | Q34591740 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists | Q34910366 | ||
| Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis | Q35030135 | ||
| A systematic review of quasi-experimental study designs in the fields of infection control and antibiotic resistance. | Q36152891 | ||
| Evolving trends in infective endocarditis | Q36388010 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). | Q36898180 | ||
| Epidemiology and economic impact of meticillin-resistant Staphylococcus aureus: review and analysis of the literature | Q36930855 | ||
| The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. | Q37981103 | ||
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 | ||
| daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q42197385 | ||
| A multicenter study evaluating the current strategies for isolating Staphylococcus aureus strains with reduced susceptibility to glycopeptides | Q42912582 | ||
| Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection | Q44320945 | ||
| Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia | Q44453815 | ||
| Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections | Q46431265 | ||
| Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia | Q46554474 | ||
| Staphylococcus aureus endocarditis: a consequence of medical progress | Q46561771 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes | Q46983556 | ||
| Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia. | Q51020085 | ||
| Vancomycin: we can't get there from here. | Q51608468 | ||
| The use and interpretation of quasi-experimental studies in infectious diseases. | Q53894802 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P304 | page(s) | 3-10 | |
| P577 | publication date | 2013-01-01 | |
| P1433 | published in | Pharmacotherapy | Q7180800 |
| P1476 | title | Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia | |
| P478 | volume | 33 |
| Q37263289 | A current perspective on daptomycin for the clinical microbiologist |
| Q30240918 | A global call from five countries to collaborate in antibiotic stewardship: united we succeed, divided we might fail. |
| Q28068503 | Antimicrobial Stewardship: How the Microbiology Laboratory Can Right the Ship |
| Q38179949 | Automated alerts coupled with antimicrobial stewardship intervention lead to decreases in length of stay in patients with gram-negative bacteremia |
| Q38232494 | Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy |
| Q45230350 | Calming the "perfect storm" in methicillin-resistant Staphylococcus aureus bacteremia: a call for a more balanced discussion. |
| Q35084162 | Cost-effectiveness and pricing of antibacterial drugs |
| Q37287739 | Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections |
| Q37544510 | Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. |
| Q38609253 | Diversity of Multidrug Efflux Genes and Phenotypic Evaluation of the In vitro Resistance Dynamics of Clinical Staphylococcus Aureus Isolates Using Methicillin; a Model β-lactam |
| Q38275128 | Economic features of antibiotic resistance: the case of methicillin-resistant Staphylococcus aureus. |
| Q36856946 | Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? |
| Q40181370 | Reply to Bush and Kaye |
| Q42931749 | Reply to Eschenauer et al. |
| Q41561992 | Telavancin in vitro activity against a collection of methicillin-resistant Staphylococcus aureus isolates, including resistant subsets, from the United States |
| Q33885191 | The Whole Price of Vancomycin: Toxicities, Troughs, and Time |
| Q42250762 | Trends in the susceptibility of methicillin-resistant Staphylococcus aureus to nine antimicrobial agents, including ceftobiprole, nemonoxacin, and tyrothricin: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006-2010. |
| Q38164663 | Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. |
| Q64239751 | Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review |
Search more.